Moreover, recent evidence suggests that SGLT2 inhibitors, now a mainstay therapy for diabetic nephropathy, may exert part of their renoprotective effects through restoration of renal SIRT1 activity and improvement of mitochondrial integrity, thereby indirectly modulating NAD+ metabolism [35,36]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.